ScreenPro Security (CSE: SCRN) this morning announced that it has launched a new line of business as of this morning. The company is now providing rapid antigen testing for both corporations and individuals via a recently approved rapid antigen test.
The new line of business will see the company administer rapid test kits via trained nurses, with results expected within ten minutes of testing. Test kits are to cost consumers or corporations as little as $60 per kit, with the company identifying the test as an affordable option for testing that “lowers the financial barrier for testing.”
Use of the kit will see a nurse administer a nasal swab to the client. If a test proves positive, a PCR test will then be conducted for an added layer of testing and security. The test, which has over 94% sensitivity, is envision by ScreenPro to provide a turnkey solution to clients looking to ensure that everyone within their facility has a negative COVID-19 test prior to being allowed entry.
Test kits have reportedly already been rolled out to clients, with positive responses from the program already being received.
ScreenPro Security last traded at $0.11 on the CSE.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.